| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Neoplasms | 18 | 2022 | 446 | 5.310 |
Why?
|
| Early Detection of Cancer | 33 | 2025 | 529 | 4.510 |
Why?
|
| Colorectal Neoplasms | 39 | 2024 | 622 | 4.410 |
Why?
|
| Colonoscopy | 20 | 2024 | 257 | 2.430 |
Why?
|
| Breast Neoplasms | 24 | 2025 | 969 | 2.360 |
Why?
|
| Survivors | 6 | 2018 | 157 | 2.350 |
Why?
|
| Neoplasm Recurrence, Local | 11 | 2018 | 243 | 2.050 |
Why?
|
| Humans | 104 | 2025 | 17314 | 2.010 |
Why?
|
| Aged | 72 | 2025 | 6084 | 1.900 |
Why?
|
| Mass Screening | 20 | 2024 | 672 | 1.880 |
Why?
|
| Uterine Cervical Neoplasms | 6 | 2025 | 131 | 1.700 |
Why?
|
| Middle Aged | 69 | 2025 | 7836 | 1.620 |
Why?
|
| Female | 80 | 2025 | 12396 | 1.590 |
Why?
|
| Electronic Health Records | 7 | 2023 | 704 | 1.470 |
Why?
|
| Occult Blood | 13 | 2024 | 155 | 1.470 |
Why?
|
| Algorithms | 5 | 2020 | 223 | 1.410 |
Why?
|
| Uterine Cervical Dysplasia | 4 | 2025 | 10 | 1.410 |
Why?
|
| Cancer Survivors | 4 | 2025 | 101 | 1.390 |
Why?
|
| Papillomavirus Infections | 4 | 2025 | 142 | 1.370 |
Why?
|
| Postmenopause | 11 | 2009 | 248 | 1.300 |
Why?
|
| Health Services Research | 4 | 2016 | 202 | 1.280 |
Why?
|
| Adaptation, Psychological | 4 | 2018 | 78 | 1.220 |
Why?
|
| Colposcopy | 3 | 2025 | 6 | 1.220 |
Why?
|
| Guideline Adherence | 4 | 2025 | 149 | 1.100 |
Why?
|
| Washington | 19 | 2020 | 384 | 1.050 |
Why?
|
| Male | 46 | 2024 | 9804 | 1.050 |
Why?
|
| Animal Assisted Therapy | 2 | 2017 | 5 | 1.030 |
Why?
|
| Aged, 80 and over | 22 | 2024 | 1925 | 1.030 |
Why?
|
| Child, Hospitalized | 2 | 2017 | 14 | 1.020 |
Why?
|
| Antidepressive Agents | 3 | 2015 | 142 | 0.970 |
Why?
|
| United States | 20 | 2025 | 3866 | 0.960 |
Why?
|
| Adenoma | 7 | 2024 | 95 | 0.920 |
Why?
|
| Risk Factors | 21 | 2025 | 3258 | 0.910 |
Why?
|
| Adult | 29 | 2025 | 7500 | 0.910 |
Why?
|
| Papillomavirus Vaccines | 1 | 2025 | 114 | 0.850 |
Why?
|
| Practice Guidelines as Topic | 7 | 2025 | 310 | 0.840 |
Why?
|
| Comparative Effectiveness Research | 3 | 2013 | 62 | 0.790 |
Why?
|
| Epidemiologic Methods | 2 | 2012 | 72 | 0.760 |
Why?
|
| Exercise | 8 | 2008 | 515 | 0.750 |
Why?
|
| Bias | 4 | 2022 | 96 | 0.720 |
Why?
|
| Diabetes Mellitus | 2 | 2018 | 452 | 0.720 |
Why?
|
| Surveys and Questionnaires | 10 | 2019 | 1282 | 0.690 |
Why?
|
| Colonic Neoplasms | 2 | 2019 | 163 | 0.690 |
Why?
|
| Neoplasms, Second Primary | 4 | 2018 | 31 | 0.670 |
Why?
|
| Delivery of Health Care, Integrated | 8 | 2017 | 535 | 0.660 |
Why?
|
| Quality of Life | 4 | 2018 | 499 | 0.660 |
Why?
|
| Return to Work | 1 | 2019 | 2 | 0.640 |
Why?
|
| Patient Acceptance of Health Care | 4 | 2022 | 381 | 0.640 |
Why?
|
| Oropharyngeal Neoplasms | 1 | 2019 | 6 | 0.630 |
Why?
|
| Follow-Up Studies | 10 | 2020 | 1151 | 0.630 |
Why?
|
| Adenocarcinoma | 4 | 2022 | 173 | 0.610 |
Why?
|
| Proportional Hazards Models | 6 | 2019 | 701 | 0.610 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2019 | 56 | 0.600 |
Why?
|
| Retrospective Studies | 14 | 2025 | 2415 | 0.590 |
Why?
|
| Time Factors | 7 | 2019 | 1039 | 0.580 |
Why?
|
| Age Factors | 5 | 2024 | 878 | 0.570 |
Why?
|
| Sensitivity and Specificity | 6 | 2022 | 298 | 0.540 |
Why?
|
| Liver Cirrhosis | 1 | 2017 | 41 | 0.540 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2017 | 29 | 0.540 |
Why?
|
| Health Expenditures | 1 | 2018 | 72 | 0.530 |
Why?
|
| Liver Neoplasms | 1 | 2017 | 42 | 0.530 |
Why?
|
| Cohort Studies | 14 | 2025 | 2514 | 0.520 |
Why?
|
| Anticarcinogenic Agents | 1 | 2016 | 13 | 0.500 |
Why?
|
| Feces | 2 | 2016 | 85 | 0.500 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 357 | 0.500 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 191 | 0.500 |
Why?
|
| Predictive Value of Tests | 4 | 2025 | 342 | 0.500 |
Why?
|
| Employment | 1 | 2016 | 44 | 0.490 |
Why?
|
| Oncology Service, Hospital | 1 | 2015 | 1 | 0.490 |
Why?
|
| Bonding, Human-Pet | 1 | 2015 | 2 | 0.490 |
Why?
|
| Young Adult | 12 | 2025 | 2465 | 0.490 |
Why?
|
| Endometrial Neoplasms | 2 | 2007 | 37 | 0.490 |
Why?
|
| Colonic Polyps | 3 | 2023 | 36 | 0.490 |
Why?
|
| Research | 2 | 2013 | 61 | 0.490 |
Why?
|
| Mammography | 3 | 2015 | 168 | 0.480 |
Why?
|
| Population Surveillance | 1 | 2017 | 252 | 0.480 |
Why?
|
| Paroxetine | 1 | 2015 | 14 | 0.480 |
Why?
|
| Primary Prevention | 1 | 2016 | 62 | 0.480 |
Why?
|
| Aspirin | 1 | 2016 | 63 | 0.480 |
Why?
|
| Insurance Coverage | 1 | 2016 | 104 | 0.470 |
Why?
|
| Psychometrics | 1 | 2015 | 119 | 0.460 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 302 | 0.450 |
Why?
|
| Insurance, Health | 1 | 2016 | 170 | 0.450 |
Why?
|
| Antidepressive Agents, Tricyclic | 2 | 2013 | 8 | 0.450 |
Why?
|
| Carcinoma, Ductal, Breast | 2 | 2012 | 52 | 0.440 |
Why?
|
| Professional Role | 1 | 2013 | 10 | 0.430 |
Why?
|
| Delivery of Health Care | 6 | 2022 | 390 | 0.430 |
Why?
|
| Depressive Disorder | 1 | 2015 | 185 | 0.420 |
Why?
|
| Cardiovascular Diseases | 2 | 2016 | 532 | 0.420 |
Why?
|
| Epidemiologic Studies | 1 | 2013 | 29 | 0.420 |
Why?
|
| Medical Oncology | 1 | 2013 | 32 | 0.410 |
Why?
|
| Preventive Medicine | 1 | 2013 | 22 | 0.400 |
Why?
|
| Behavioral Sciences | 1 | 2012 | 2 | 0.400 |
Why?
|
| Clinical Trials as Topic | 1 | 2013 | 120 | 0.400 |
Why?
|
| Reminder Systems | 5 | 2017 | 74 | 0.390 |
Why?
|
| Papillomaviridae | 4 | 2025 | 61 | 0.390 |
Why?
|
| Health Personnel | 1 | 2013 | 126 | 0.390 |
Why?
|
| Health Status Indicators | 1 | 2012 | 59 | 0.380 |
Why?
|
| Heart Diseases | 1 | 2012 | 71 | 0.370 |
Why?
|
| Health Policy | 1 | 2012 | 109 | 0.370 |
Why?
|
| Logistic Models | 6 | 2018 | 879 | 0.350 |
Why?
|
| Serotonin Uptake Inhibitors | 1 | 2011 | 46 | 0.340 |
Why?
|
| Registries | 6 | 2019 | 460 | 0.340 |
Why?
|
| Databases, Factual | 1 | 2011 | 304 | 0.330 |
Why?
|
| Animals | 3 | 2017 | 280 | 0.330 |
Why?
|
| Postal Service | 5 | 2019 | 72 | 0.320 |
Why?
|
| Estrogen Replacement Therapy | 2 | 2007 | 100 | 0.320 |
Why?
|
| Drug Prescriptions | 1 | 2011 | 146 | 0.320 |
Why?
|
| Histamine H2 Antagonists | 1 | 2009 | 13 | 0.310 |
Why?
|
| Disease Progression | 3 | 2016 | 259 | 0.310 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 24 | 0.310 |
Why?
|
| Case-Control Studies | 8 | 2023 | 1098 | 0.300 |
Why?
|
| Patient Compliance | 4 | 2017 | 277 | 0.300 |
Why?
|
| Odds Ratio | 7 | 2019 | 640 | 0.300 |
Why?
|
| Health Care Costs | 1 | 2010 | 207 | 0.290 |
Why?
|
| Gonadal Steroid Hormones | 2 | 2005 | 27 | 0.290 |
Why?
|
| Breast | 1 | 2009 | 84 | 0.290 |
Why?
|
| Research Design | 5 | 2013 | 336 | 0.280 |
Why?
|
| Estrogens | 2 | 2007 | 60 | 0.280 |
Why?
|
| Progestins | 1 | 2007 | 25 | 0.270 |
Why?
|
| Hypertension | 2 | 2025 | 469 | 0.270 |
Why?
|
| Adolescent | 7 | 2025 | 3538 | 0.270 |
Why?
|
| Common Cold | 1 | 2006 | 2 | 0.260 |
Why?
|
| Dogs | 2 | 2017 | 19 | 0.260 |
Why?
|
| Lung Neoplasms | 3 | 2022 | 268 | 0.260 |
Why?
|
| Thinness | 1 | 2006 | 31 | 0.250 |
Why?
|
| Bone Density | 1 | 2006 | 94 | 0.240 |
Why?
|
| Hospitals, Pediatric | 2 | 2017 | 71 | 0.240 |
Why?
|
| Cost-Benefit Analysis | 2 | 2024 | 226 | 0.240 |
Why?
|
| Neoplasm Staging | 7 | 2017 | 338 | 0.240 |
Why?
|
| Trastuzumab | 1 | 2025 | 19 | 0.240 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2018 | 65 | 0.240 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2025 | 9 | 0.240 |
Why?
|
| Overweight | 5 | 2007 | 266 | 0.230 |
Why?
|
| Incidence | 4 | 2025 | 1266 | 0.230 |
Why?
|
| Anxiety | 2 | 2018 | 154 | 0.230 |
Why?
|
| SEER Program | 5 | 2020 | 92 | 0.230 |
Why?
|
| Patient Navigation | 2 | 2015 | 18 | 0.230 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2025 | 52 | 0.220 |
Why?
|
| Follicle Stimulating Hormone | 1 | 2004 | 3 | 0.220 |
Why?
|
| Risk Assessment | 5 | 2019 | 1076 | 0.220 |
Why?
|
| Estradiol | 1 | 2004 | 23 | 0.220 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2004 | 21 | 0.220 |
Why?
|
| Patient-Centered Care | 2 | 2016 | 186 | 0.210 |
Why?
|
| Health Status | 1 | 2005 | 293 | 0.210 |
Why?
|
| Vaginal Smears | 4 | 2025 | 47 | 0.210 |
Why?
|
| Biomarkers, Tumor | 1 | 2004 | 145 | 0.200 |
Why?
|
| Ovarian Neoplasms | 2 | 2014 | 52 | 0.200 |
Why?
|
| Primary Health Care | 3 | 2022 | 726 | 0.190 |
Why?
|
| Survival Rate | 2 | 2013 | 252 | 0.190 |
Why?
|
| Cross-Sectional Studies | 4 | 2024 | 1280 | 0.190 |
Why?
|
| Reproductive History | 2 | 2017 | 17 | 0.190 |
Why?
|
| Linear Models | 4 | 2011 | 206 | 0.170 |
Why?
|
| Tamoxifen | 2 | 2018 | 55 | 0.170 |
Why?
|
| Obesity | 5 | 2007 | 814 | 0.170 |
Why?
|
| Confounding Factors (Epidemiology) | 2 | 2013 | 84 | 0.170 |
Why?
|
| Intestinal Polyps | 1 | 2020 | 7 | 0.170 |
Why?
|
| Patient Selection | 2 | 2012 | 176 | 0.160 |
Why?
|
| Vaccination | 1 | 2025 | 688 | 0.160 |
Why?
|
| Prostatic Neoplasms | 1 | 2022 | 263 | 0.160 |
Why?
|
| Confidence Intervals | 4 | 2013 | 231 | 0.160 |
Why?
|
| Interviews as Topic | 2 | 2013 | 306 | 0.160 |
Why?
|
| Child | 2 | 2017 | 2403 | 0.160 |
Why?
|
| Symptom Assessment | 1 | 2019 | 6 | 0.160 |
Why?
|
| Socioeconomic Factors | 3 | 2019 | 605 | 0.150 |
Why?
|
| Cytochrome P-450 CYP2D6 | 1 | 2018 | 1 | 0.150 |
Why?
|
| Educational Status | 1 | 2019 | 177 | 0.150 |
Why?
|
| Motivation | 1 | 2019 | 115 | 0.150 |
Why?
|
| Treatment Outcome | 6 | 2015 | 1160 | 0.150 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 169 | 0.150 |
Why?
|
| Diabetes Complications | 1 | 2018 | 105 | 0.140 |
Why?
|
| Healthcare Disparities | 2 | 2019 | 202 | 0.140 |
Why?
|
| Ultrasonography | 1 | 2017 | 33 | 0.140 |
Why?
|
| Pediatric Nursing | 1 | 2017 | 4 | 0.140 |
Why?
|
| Nurses | 2 | 2015 | 33 | 0.130 |
Why?
|
| Comorbidity | 2 | 2016 | 560 | 0.130 |
Why?
|
| Contraceptives, Oral | 1 | 2017 | 25 | 0.130 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2016 | 16 | 0.130 |
Why?
|
| Analgesics, Opioid | 1 | 2019 | 245 | 0.130 |
Why?
|
| Pilot Projects | 1 | 2017 | 211 | 0.130 |
Why?
|
| Androgens | 2 | 2008 | 14 | 0.130 |
Why?
|
| Specimen Handling | 1 | 2016 | 24 | 0.120 |
Why?
|
| Antihypertensive Agents | 1 | 2017 | 154 | 0.120 |
Why?
|
| Genetic Counseling | 2 | 2014 | 27 | 0.120 |
Why?
|
| Risk | 2 | 2015 | 496 | 0.120 |
Why?
|
| Medical Records | 1 | 2015 | 91 | 0.120 |
Why?
|
| Hypoglycemic Agents | 1 | 2017 | 250 | 0.120 |
Why?
|
| Health Surveys | 1 | 2016 | 245 | 0.120 |
Why?
|
| Testosterone | 2 | 2005 | 22 | 0.120 |
Why?
|
| Inpatients | 1 | 2015 | 79 | 0.120 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2014 | 312 | 0.110 |
Why?
|
| Outpatients | 1 | 2015 | 101 | 0.110 |
Why?
|
| Prognosis | 3 | 2015 | 603 | 0.110 |
Why?
|
| Aromatase | 2 | 2004 | 9 | 0.110 |
Why?
|
| Adipose Tissue | 2 | 2004 | 65 | 0.110 |
Why?
|
| Self Efficacy | 1 | 2014 | 68 | 0.110 |
Why?
|
| Depressive Disorder, Major | 1 | 2015 | 100 | 0.110 |
Why?
|
| Cardiovascular Agents | 1 | 2014 | 22 | 0.110 |
Why?
|
| Patient Advocacy | 1 | 2013 | 13 | 0.110 |
Why?
|
| Reagent Kits, Diagnostic | 1 | 2013 | 9 | 0.110 |
Why?
|
| Utilization Review | 1 | 2013 | 42 | 0.100 |
Why?
|
| Observer Variation | 1 | 2013 | 36 | 0.100 |
Why?
|
| Selection Bias | 1 | 2013 | 16 | 0.100 |
Why?
|
| Observation | 1 | 2013 | 20 | 0.100 |
Why?
|
| Patient Care Planning | 1 | 2013 | 45 | 0.100 |
Why?
|
| Health Promotion | 1 | 2016 | 279 | 0.100 |
Why?
|
| Counseling | 1 | 2015 | 174 | 0.100 |
Why?
|
| Societies, Medical | 1 | 2013 | 71 | 0.100 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2013 | 26 | 0.100 |
Why?
|
| Continuity of Patient Care | 2 | 2011 | 103 | 0.100 |
Why?
|
| Patient Preference | 1 | 2013 | 49 | 0.100 |
Why?
|
| Recurrence | 1 | 2013 | 165 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2013 | 202 | 0.100 |
Why?
|
| Effect Modifier, Epidemiologic | 1 | 2012 | 8 | 0.100 |
Why?
|
| Translational Medical Research | 1 | 2012 | 33 | 0.100 |
Why?
|
| Outcome and Process Assessment (Health Care) | 1 | 2012 | 97 | 0.100 |
Why?
|
| Ovariectomy | 1 | 2012 | 9 | 0.100 |
Why?
|
| Clinical Coding | 1 | 2011 | 11 | 0.090 |
Why?
|
| Program Evaluation | 1 | 2012 | 205 | 0.090 |
Why?
|
| Drug Administration Schedule | 2 | 2012 | 99 | 0.090 |
Why?
|
| Anti-Bacterial Agents | 1 | 2013 | 143 | 0.090 |
Why?
|
| Specialization | 1 | 2011 | 21 | 0.090 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 664 | 0.090 |
Why?
|
| Weight Loss | 2 | 2022 | 294 | 0.090 |
Why?
|
| Longitudinal Studies | 3 | 2020 | 674 | 0.090 |
Why?
|
| False Positive Reactions | 1 | 2010 | 26 | 0.080 |
Why?
|
| Depression | 1 | 2015 | 486 | 0.080 |
Why?
|
| California | 3 | 2025 | 2311 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2012 | 235 | 0.080 |
Why?
|
| Anti-Ulcer Agents | 1 | 2009 | 5 | 0.080 |
Why?
|
| Ambulatory Care | 1 | 2011 | 225 | 0.080 |
Why?
|
| Phenotype | 2 | 2020 | 149 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2009 | 58 | 0.080 |
Why?
|
| Prospective Studies | 1 | 2012 | 1226 | 0.080 |
Why?
|
| Health Behavior | 2 | 2012 | 346 | 0.070 |
Why?
|
| Telephone | 3 | 2017 | 150 | 0.070 |
Why?
|
| Referral and Consultation | 1 | 2009 | 157 | 0.070 |
Why?
|
| Carcinoma, Lobular | 1 | 2007 | 10 | 0.070 |
Why?
|
| Sigmoidoscopy | 3 | 2013 | 65 | 0.070 |
Why?
|
| Pregnancy | 2 | 2023 | 1463 | 0.070 |
Why?
|
| Catechol O-Methyltransferase | 2 | 2004 | 2 | 0.070 |
Why?
|
| Prolactin | 1 | 2007 | 4 | 0.070 |
Why?
|
| Medicare | 2 | 2017 | 192 | 0.060 |
Why?
|
| Respiratory Tract Infections | 1 | 2006 | 51 | 0.060 |
Why?
|
| Lipoproteins | 1 | 2006 | 13 | 0.060 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 535 | 0.060 |
Why?
|
| Androstenedione | 1 | 2005 | 3 | 0.060 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2005 | 6 | 0.060 |
Why?
|
| Dehydroepiandrosterone | 1 | 2005 | 7 | 0.060 |
Why?
|
| Phytotherapy | 1 | 2005 | 12 | 0.060 |
Why?
|
| Outcome Assessment (Health Care) | 2 | 2017 | 215 | 0.060 |
Why?
|
| Exercise Therapy | 1 | 2006 | 72 | 0.060 |
Why?
|
| Texas | 1 | 2025 | 41 | 0.060 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2024 | 37 | 0.060 |
Why?
|
| Menstrual Cycle | 1 | 2004 | 5 | 0.060 |
Why?
|
| Body Mass Index | 5 | 2007 | 937 | 0.060 |
Why?
|
| Parity | 1 | 2004 | 57 | 0.060 |
Why?
|
| Probability | 1 | 2004 | 71 | 0.060 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2004 | 5 | 0.050 |
Why?
|
| Steroid 17-alpha-Hydroxylase | 1 | 2004 | 5 | 0.050 |
Why?
|
| Age Distribution | 1 | 2004 | 239 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2004 | 62 | 0.050 |
Why?
|
| Office Visits | 2 | 2016 | 73 | 0.050 |
Why?
|
| Influenza Vaccines | 1 | 2006 | 292 | 0.050 |
Why?
|
| Papanicolaou Test | 1 | 2022 | 37 | 0.050 |
Why?
|
| Prostate-Specific Antigen | 1 | 2022 | 75 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 372 | 0.040 |
Why?
|
| Self Report | 2 | 2013 | 257 | 0.040 |
Why?
|
| Proto-Oncogene Proteins B-raf | 1 | 2020 | 15 | 0.040 |
Why?
|
| Data Warehousing | 1 | 2020 | 3 | 0.040 |
Why?
|
| Pandemics | 1 | 2022 | 287 | 0.040 |
Why?
|
| DNA Methylation | 1 | 2020 | 44 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2019 | 33 | 0.040 |
Why?
|
| Mutation | 1 | 2020 | 132 | 0.040 |
Why?
|
| Financial Support | 1 | 2019 | 6 | 0.040 |
Why?
|
| Biopsy | 1 | 2019 | 82 | 0.040 |
Why?
|
| Demography | 1 | 2019 | 93 | 0.040 |
Why?
|
| Age of Onset | 1 | 2019 | 70 | 0.040 |
Why?
|
| Cytochrome P-450 CYP2D6 Inhibitors | 1 | 2018 | 1 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 55 | 0.040 |
Why?
|
| Health Knowledge, Attitudes, Practice | 2 | 2014 | 367 | 0.040 |
Why?
|
| Attitude to Health | 1 | 2019 | 147 | 0.040 |
Why?
|
| Sulfonylurea Compounds | 1 | 2017 | 25 | 0.030 |
Why?
|
| Metformin | 1 | 2017 | 50 | 0.030 |
Why?
|
| Insulin | 1 | 2017 | 188 | 0.030 |
Why?
|
| Aftercare | 1 | 2016 | 47 | 0.030 |
Why?
|
| Family Health | 1 | 2014 | 45 | 0.030 |
Why?
|
| Alleles | 2 | 2004 | 80 | 0.030 |
Why?
|
| Genotype | 2 | 2004 | 223 | 0.030 |
Why?
|
| Sex Factors | 1 | 2015 | 603 | 0.030 |
Why?
|
| Idaho | 1 | 2013 | 24 | 0.030 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 65 | 0.020 |
Why?
|
| Aromatase Inhibitors | 1 | 2012 | 33 | 0.020 |
Why?
|
| Treatment Refusal | 1 | 2012 | 30 | 0.020 |
Why?
|
| Residence Characteristics | 1 | 2014 | 253 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2012 | 270 | 0.020 |
Why?
|
| Analysis of Variance | 1 | 2011 | 139 | 0.020 |
Why?
|
| Nursing Care | 1 | 2010 | 4 | 0.020 |
Why?
|
| Nursing Staff, Hospital | 1 | 2010 | 10 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 26 | 0.020 |
Why?
|
| Quality Control | 1 | 2010 | 41 | 0.020 |
Why?
|
| Allied Health Personnel | 1 | 2010 | 12 | 0.020 |
Why?
|
| Continental Population Groups | 1 | 2012 | 286 | 0.020 |
Why?
|
| Data Collection | 1 | 2010 | 238 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2011 | 397 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 2008 | 10 | 0.020 |
Why?
|
| Adiposity | 1 | 2008 | 67 | 0.020 |
Why?
|
| Long-Term Care | 1 | 2007 | 21 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2007 | 163 | 0.020 |
Why?
|
| Radioimmunoassay | 1 | 2004 | 4 | 0.010 |
Why?
|
| DNA | 1 | 2004 | 23 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2004 | 52 | 0.010 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2004 | 2 | 0.010 |
Why?
|
| Body Composition | 1 | 2004 | 91 | 0.010 |
Why?
|
| Body Weight | 1 | 2004 | 203 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2004 | 203 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2004 | 363 | 0.010 |
Why?
|